Page last updated: 2024-11-05

4-methylpyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methylpyridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

4-methylpyridine : A methylpyridine in which the methyl substituent is at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7963
CHEMBL ID15544
CHEBI ID32547
MeSH IDM0504558

Synonyms (68)

Synonym
einecs 203-626-4
ai3-24111
nsc 18252
gamma-methylpyridine
ccris 1723
hsdb 5386
.gamma.-picoline
4-picoline
.gamma.-methylpyridine
nsc-18252
p-picoline
wln: t6nj d1
4-methylpyridine
108-89-4
p-methylpyridine
nsc18252
ba 35846
pyridine, 4-methyl-
gamma-picoline
4-mepy
CHEBI:32547 ,
PK04_181300
RTE3_000025
inchi=1/c6h7n/c1-6-2-4-7-5-3-6/h2-5h,1h
4-methyl-pyridine (gamma-picoline)
4-methylpyridine, 99%
4-methylpyridine, 98%
NCIOPEN2_007706
4-methyl-pyridine
CHEMBL15544
P0417
AKOS000119191
A801938
A2139
NCGC00249042-01
4-methylpyridinium
tjd6v9sso7 ,
p-picoline [un2313] [flammable liquid]
unii-tjd6v9sso7
dtxsid4021892 ,
tox21_302961
NCGC00256613-01
dtxcid201892
cas-108-89-4
tox21_201400
NCGC00258951-01
BBL011459
STL146571
FT-0626621
picoline, gamma
4-methylpyridine [hsdb]
ba-35846
.gamma.-picoline [mi]
AM81280
gamma-picolin
4-pi-coline
4-methyl pyridine
Q-200501
69046-49-7
4-methyl-d1-pyridine
para-methylpyridine
4-picoline, technical, >=98.0% (gc)
F0001-0182
mfcd00006440
4-picoline, analytical reference material
Q2189778
EN300-19109
PD182276
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylpyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency0.61130.000714.592883.7951AID1259369
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.15880.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency24.33650.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency3.08960.000229.305416,493.5996AID743069
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID1134914Dissociation constant, pKa of the compound1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents.
AID30380Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-41985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30518Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -4 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID213129Inhibition of Thromboxane synthetase at 100 uM1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (30.43)18.7374
1990's0 (0.00)18.2507
2000's5 (21.74)29.6817
2010's11 (47.83)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.27 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.41 (4.65)
Search Engine Demand Index66.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]